{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:12:54Z","timestamp":1749010374200,"version":"3.41.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The authors report the case of a 66-year-old male patient who was hemodialyzed 3 times per week for chronic renal failure and treated with 100 mg of doravirine once daily in combination with dolutegravir for HIV-1. No dose adjustment is required for doravirine in cases of severe renal injury, but the effect of dialysis on its exposure is poorly understood.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods &amp; Results:<\/jats:title>\n            <jats:p>Two series of 2 samples were drawn before and after 4-hour hemodialysis and showed an average doravirine concentration decrease of 48.1 \u00b1 6.7%. The effects of hemodialysis were important, contrary to what was expected and has been previously reported. In addition, intraindividual variability was low. Nevertheless, because the concentrations reported were largely above the inhibitory concentration 50 (IC<jats:sub>50<\/jats:sub>), no dose adjustment was required.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The decrease in doravirine concentration due to hemodialysis observed in this case report was quite significant. Therefore, therapeutic drug monitoring might be recommended in certain patients undergoing doravirine treatment also on hemodialysis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001062","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T14:31:18Z","timestamp":1675348278000},"page":"133-135","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Doravirine Exposure Decreased by Dialysis in a HIV Patient: A Grand Round"],"prefix":"10.1097","volume":"45","author":[{"given":"Yeleen","family":"Fromage","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrielle","family":"Codde","sequence":"additional","affiliation":[{"name":"Department of Infectious disease, CHU de Limoges, Limoges, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France;"},{"name":"Pharmacology and Transplantation, INSERM U1248, Universit\u00e9 de Limoges, Limoges, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Labriffe","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France;"},{"name":"Pharmacology and Transplantation, INSERM U1248, Universit\u00e9 de Limoges, Limoges, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh P.","family":"L\u00ea","sequence":"additional","affiliation":[{"name":"AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department; and"},{"name":"Universit\u00e9 Paris Cit\u00e9, Inserm, Optimisation Th\u00e9rapeutique en Neuropsychopharmacologie, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Faucher","sequence":"additional","affiliation":[{"name":"Department of Infectious disease, CHU de Limoges, Limoges, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-0695","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France;"},{"name":"Pharmacology and Transplantation, INSERM U1248, Universit\u00e9 de Limoges, Limoges, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"003266","DOI":"10.1128\/AAC.00326-18","article-title":"Severe renal impairment has minimal impact on doravirine pharmacokinetics","volume":"62","author":"Ankrom","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.bmcl.2013.12.070","article-title":"Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses","volume":"24","author":"C\u00f4t\u00e9","year":"2014","journal-title":"Bioorg Med Chem Lett."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/jac\/dkac126","article-title":"Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease","volume":"77","author":"Molt\u00f3","year":"2022","journal-title":"J Antimicrob Chemother."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.03131-15","article-title":"Removal of dolutegravir by hemodialysis in HIV-infected patients with end-stage renal disease","volume":"60","author":"Molt\u00f3","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ki.1994.28","article-title":"Vancomycin redistribution: dosing recommendations following high-flux hemodialysis","volume":"45","author":"Pollard","year":"1994","journal-title":"Kidney Int."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/jcph.857","article-title":"Moderate hepatic impairment does not affect doravirine pharmacokinetics","volume":"57","author":"Khalilieh","year":"2017","journal-title":"J Clin Pharmacol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"e02502","DOI":"10.1128\/AAC.02502-18","article-title":"Population pharmacokinetics of doravirine and exposure-response analysis in individuals with HIV-1","volume":"63","author":"Yee","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"024922","DOI":"10.1128\/AAC.02492-18","article-title":"Vitro evaluation of the drug interaction potential of doravirine","volume":"63","author":"Bleasby","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","article-title":"Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine","volume":"58","author":"Boyle","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3851\/IMP2920","article-title":"Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects","volume":"20","author":"Anderson","year":"2015","journal-title":"Antivir Ther."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/cid\/ciab835","article-title":"Total and unbound doravirine concentrations and viral suppression in CSF","volume":"74","author":"Tiraboschi","year":"2022","journal-title":"Clin Infect Dis."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/jac\/dkab001","article-title":"Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis","volume":"76","author":"Kobayashi","year":"2021","journal-title":"J Antimicrob Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:17:47Z","timestamp":1748971067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001062","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"2022-09-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}